Free Trial

Brokers Offer Predictions for Vitalhub FY2025 Earnings

Vitalhub logo with Medical background

Key Points

  • National Bank Financial has lowered its FY2025 earnings per share (EPS) estimate for Vitalhub from $0.16 to $0.13, while maintaining a "Strong-Buy" rating on the stock.
  • Multiple analysts have raised their target prices for Vitalhub, with TD Securities setting a new target of C$16.00 and Scotiabank adjusting theirs to C$14.50.
  • Vitalhub shares opened at C$13.51 with a market capitalization of C$730.79 million, experiencing a 52-week high of C$14.64 and a low of C$7.62.
  • Five stocks to consider instead of Vitalhub.

Vitalhub Corp. (TSE:VHI - Free Report) - Equities researchers at National Bank Financial reduced their FY2025 earnings per share estimates for Vitalhub in a note issued to investors on Monday, August 11th. National Bank Financial analyst J. Shao now expects that the company will earn $0.13 per share for the year, down from their previous forecast of $0.16. National Bank Financial has a "Strong-Buy" rating on the stock. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. National Bank Financial also issued estimates for Vitalhub's Q4 2025 earnings at $0.03 EPS, FY2026 earnings at $0.18 EPS and FY2027 earnings at $0.29 EPS.

Several other research firms have also issued reports on VHI. TD Securities upped their price objective on Vitalhub from C$15.00 to C$16.00 and gave the company a "buy" rating in a research note on Monday, August 11th. National Bankshares set a C$14.00 target price on Vitalhub and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Raymond James Financial increased their target price on Vitalhub from C$14.50 to C$15.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th. Finally, Scotiabank increased their target price on Vitalhub from C$14.00 to C$14.50 and gave the stock an "outperform" rating in a research note on Friday, June 20th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vitalhub presently has a consensus rating of "Buy" and a consensus price target of C$13.75.

View Our Latest Analysis on Vitalhub

Vitalhub Trading Up 1.2%

TSE:VHI traded up C$0.15 on Wednesday, hitting C$12.90. The company's stock had a trading volume of 180,106 shares, compared to its average volume of 149,530. The stock has a fifty day moving average of C$12.13 and a two-hundred day moving average of C$10.92. The firm has a market capitalization of C$697.79 million, a P/E ratio of 209.81, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26. Vitalhub has a one year low of C$7.62 and a one year high of C$14.64.

About Vitalhub

(Get Free Report)

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.

Featured Articles

Earnings History and Estimates for Vitalhub (TSE:VHI)

Should You Invest $1,000 in Vitalhub Right Now?

Before you consider Vitalhub, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.

While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.